“Our portfolio company structure provides a cost-efficient central support and a solid financial base while allowing for flexible financing and partnering”
Cureteq and portfolio companies
In-licensed drug candidates are owned and developed by existing or newly formed biotech companies, also called ‘teqs’.
This hybrid model combines the speed and agility of biotech companies while retaining some of the benefits of larger organisations, such as access to internal expertise, resources and financial backing.
- Portfolio companies are agile, cost efficient and responsible for drug development
- Teams have full access to Cureteq’s platform, AI engine and competencies across the group
- As ‘teqs’ mature, they may operate independently with their own governance, fully compatible with the venture capital investment and operating model
Oncoteq is founded and seeded by Cureteq and headquartered in Zug, Switzerland, and is responsible for the development of TEQ101, TEQ102 and TEQ103.
Portfolio company still in stealth mode
Unique ownership and financing
Cureteq is privately held by Partex NV, which secures strong backing and critical mass.
Opportunities to invest in Cureteq include direct investments in a portfolio company or in Cureteq at the group level. Our financing approach is amenable to various investment models, and the flexibility also extends to a wide range of partnering models.
Are you interested in investing or partnering with Cureteq?
